Your browser doesn't support javascript.
loading
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma.
Martinez-Verbo, Laura; Veselinova, Yoana; Llinàs-Arias, Pere; García-Prieto, Carlos A; Noguera-Castells, Aleix; Pato, Miguel L; Bueno-Costa, Alberto; Campillo-Marcos, Ignacio; Villanueva, Lorea; Oliver-Caldes, Aina; Cardus, Oriol; Salsench, Sergi V; García-Ortiz, Almudena; Valeri, Antonio; Rojas, Elizabeta A; Barrena, Naroa; Gutiérrez, Norma C; Prósper, Felipe; Agirre, Xabier; Fernández de Larrea, Carlos; Martínez-López, Joaquín; Ferrer, Gerardo; Esteller, Manel.
Afiliação
  • Martinez-Verbo L; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Veselinova Y; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Llinàs-Arias P; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • García-Prieto CA; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Noguera-Castells A; Barcelona Supercomputing Center (BSC), Barcelona, Spain.
  • Pato ML; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Bueno-Costa A; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Campillo-Marcos I; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Villanueva L; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Oliver-Caldes A; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.
  • Cardus O; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
  • Salsench SV; Department of Hematology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • García-Ortiz A; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Valeri A; Department of Hematology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Rojas EA; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Barrena N; Department of Hematology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Gutiérrez NC; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Prósper F; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Agirre X; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO). Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.
  • Fernández de Larrea C; Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Martínez-López J; Hospital Universitario 12 de Octubre-Centro Nacional de Investigaciones Oncológicas (H12O-CNIO). Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain.
  • Ferrer G; Department of Hematology, University Hospital of Salamanca, IBSAL, Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Esteller M; Universidad de Navarra, Tecnun Escuela de Ingeniería, San Sebastián, Spain.
Leukemia ; 2024 Sep 24.
Article em En | MEDLINE | ID: mdl-39322713
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Leukemia Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Leukemia Ano de publicação: 2024 Tipo de documento: Article